- Home
- SNTI vs ATOS Comparison
SNTI vs ATOS Comparison
Compare SNTI & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- ATOS
- Stock Information
- Founded
- SNTI 2016
- ATOS 2009
- Country
- SNTI United States
- ATOS United States
- Employees
- SNTI N/A
- ATOS N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- ATOS Health Care
- Exchange
- SNTI Nasdaq
- ATOS Nasdaq
- Market Cap
- SNTI 85.3M
- ATOS 96.8M
- IPO Year
- SNTI N/A
- ATOS 2012
- Fundamental
- Price
- SNTI $3.10
- ATOS $0.89
- Analyst Decision
- SNTI Strong Buy
- ATOS Strong Buy
- Analyst Count
- SNTI 1
- ATOS 3
- Target Price
- SNTI $12.00
- ATOS $7.13
- AVG Volume (30 Days)
- SNTI 225.5K
- ATOS 611.2K
- Earning Date
- SNTI 05-06-2025
- ATOS 05-13-2025
- Dividend Yield
- SNTI N/A
- ATOS N/A
- EPS Growth
- SNTI N/A
- ATOS N/A
- EPS
- SNTI N/A
- ATOS N/A
- Revenue
- SNTI N/A
- ATOS N/A
- Revenue This Year
- SNTI N/A
- ATOS N/A
- Revenue Next Year
- SNTI N/A
- ATOS N/A
- P/E Ratio
- SNTI N/A
- ATOS N/A
- Revenue Growth
- SNTI N/A
- ATOS N/A
- 52 Week Low
- SNTI $1.52
- ATOS $0.55
- 52 Week High
- SNTI $16.94
- ATOS $1.74
- Technical
- Relative Strength Index (RSI)
- SNTI 41.06
- ATOS 64.44
- Support Level
- SNTI $3.10
- ATOS $0.78
- Resistance Level
- SNTI $3.61
- ATOS $0.92
- Average True Range (ATR)
- SNTI 0.40
- ATOS 0.06
- MACD
- SNTI -0.07
- ATOS 0.01
- Stochastic Oscillator
- SNTI 9.50
- ATOS 81.82
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.